Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate synthase

Cancer

Volumn 63, Issue 6 S, 1989, Pages 1008-1012

  Moran, Richard G ^a,b  

^a Departments of Pediatrics   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; THYMIDYLATE SYNTHASE;

CANCER CHEMOTHERAPY; DRUG POTENTIATION; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY;

ANIMAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG SYNERGISM; FLOXURIDINE; FLUORODEOXYURIDYLATE; FLUOROURACIL; HUMAN; LEUCOVORIN; NEOPLASMS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; THYMIDYLATE SYNTHASE;

EID: 0024581065     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19890315)63:6+<1008::AID-CNCR2820631303>3.0.CO;2-Z     Document Type: Article

References (41)

1. Prospective randomized reappraisal of 5‐fluorouracil in metastatic colorectal carcinoma. A comparative trial with 6‐thioguanine
2. Survival and response to chemotherapy for advanced colorectal adenocarcinoma: An Eastern Co‐operative Oncology Group Report
3. Randomized phase II studies in advanced colorectal carcinoma: A North Central Cancer Treatment Group study
4. Chemotherapy of advanced colorectal carcinoma: Fluorouracil alone versus two drug combinations using fluorouracil. hydroxyurea, semustine, dacarbazine, razoxane and mitomycin. A phase III study by the Eastern Cooperative Oncology Group
5. 5‐Fluorouracil plus leucovorin in cancer therapy
6. Overview of current status and future direction of clinical trials with 5‐fluorouracil in combination with folinic acid
7. Overview of clinical trials using F‐fluorouracil, and leucovorin for the treatment of colorectal cancer
8. Potentiation of 5‐fluorouracil effect by leucovorin
9. Cytotoxicity of 5‐fluoro‐2′‐deoxyuridine: Requirement for reduced folate cofactors and antogonism by methotrexate
10. Leucovorin increases the toxicity of 5‐fluorouracil: Phase 1 clinical pharmacological trials
11. Treatment of advanced colorectal and gastric adenocarcinomas with 5‐FU combined with high‐dose folinic acid: A pilot study
12. Phase I‐II trial of high‐dose calcium leucovorin and 5‐fluorouracil in advanced colorectal cancer
13. Studies on fluorinated pyrimidines. II. Effects on transplanted tumors
14. Basis for natural variation in sensitivity to 5‐fluorouracil in mouse and human cells in culture
15. Assessment of growth‐limiting events caused by 5‐fluorouracil in mouse and in human cells
16. Effect of excess folates and deoxyinosine on the activity and site of action of fluorouracil
17. Basis for the effect of leucovorin on the activity and site of action of 5‐fluorouracil in human cells
18. Relationship of dUMP and free FdUMP pools to inhibition of thymidylate synthetase by 5‐fluorouracil
19. Folinic acid augmentation of the effects of fluoropyrimidines on mouse and human leukemic cells
20. Cytotoxicity of floxuridine and 5‐fluorouracil in human T‐lymphoblast leukemia cells: Enhancement by leucovorin
21. Biochemical determinants of responsiveness to 5‐fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice
22. Thymidylate synthase and its interaction with 5‐fluoro‐2′‐deoxyuridylate
23. Effect of 5,10‐methylenetetra‐hydrofolate and the dissociation of fluoro‐2′‐deoxyuridylate from thymidylate synthetase: Evidence for an ordered mechanism
24. Mechanism of interaction of thymidylate synthetase with 5‐fluorodeoxyuridylate
25. Structures of reversible and irreversible complexes of thymidylate synthetase and fluoropyrimidine nucleotides
26. Fluorinated pyrimidines and their nucleosides
27. Biochemical factors affecting the tightness of 5‐fluorodeoxyuridylate binding of thymidylate synthetase
28. Mechanism of cytotoxic synergism of fluoropyrimidines and folinic acid in mouse leukemic cells
29. Biochemical determinants of tumor sensitivity to 5‐fluorouracil: Ultrasensitive methods for the determination of 5‐fluoro‐2′‐deoxyuridylate, 2′‐deoxyuridylate, and thymidylate synthetase
30. Mechanisms of innate resistance to thymidylate synthase inhibition after 5‐fluorouracil
31. The mechanism of the fluoropyrimidine‐folinic acid synergism in mouse leukemia cells
32. Therapeutic response of leukemic mice treated with fluorinated pyrimidines and inhibitors of deoxyuridylate synthesis
33. Biochemical rationale for the synergism of 5‐fluorouracil and folinic acid
34. Cisplatin, 5‐fluorouracil, and high‐dose oral leucovorin for advanced head and neck cancer
35. The Beutner Foundation Memorial Award Lecture—Salmon, butterflies and cancer chemotherapy
36. Toxicity and antitumor activity of 5‐fluorouracil in combination with leucovorin: Role of dose schedule and route of administration of leucovorin
37. Effect of leucovorin on pools of methylenetetrahydrofolate and tetrahydrofolate in xenografts of human colon adenocarcinoma
38. New vistas for leucovorin in cancer chemotherapy
39. Stereospecificity at carbon 6 of formyltetrahydrofolate as a competitive inhibitor of transport and cytotoxicity of methotrexate in vitro
40. Interaction of methotrexate and citrovorum factor at folypolyglutamate synthetase
41. Pharmacokinetics of the diastereomers of leucovorin after intravenous and oral administration to normal subjects